| Sarcoma altered in cohorts of …ALTERED_INderived195 of 195show fewer |
|---|
| ← altered in cohorts of | MYOD1 20 / 20 cases (100 %) · ssm · soft_tissue_myod1_msk_2025 | — | — | Rhabdomyosarcoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | TP53 167 / 261 cases (64 %) · ssm · TCGA-SARC · largest of 6 cohorts | — | — | Sarcoma | 6 | Observed | gdc | graph → |
| ← altered in cohorts of | RB1 165 / 261 cases (63 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ITM2B 154 / 261 cases (59 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LPAR6 154 / 261 cases (59 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RCBTB2 154 / 261 cases (59 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CAB39L 153 / 261 cases (59 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDADC1 152 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CYSLTR2 152 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FNDC3A 152 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MLNR 152 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SETDB2 152 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MED4 151 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NUDT15 151 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PHF11 151 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RCBTB1 151 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SUCLA2 151 / 261 cases (58 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ARL11 150 / 261 cases (57 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNRG 150 / 261 cases (57 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EBPL 149 / 261 cases (57 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KPNA3 149 / 261 cases (57 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIM13 149 / 261 cases (57 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPRYD7 148 / 261 cases (57 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HTR2A 147 / 261 cases (56 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DLEU7 146 / 261 cases (56 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ESD 146 / 261 cases (56 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRCH1 146 / 261 cases (56 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LCP1 145 / 261 cases (56 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RUBCNL 145 / 261 cases (56 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SIAH3 145 / 261 cases (56 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | C13orf42 144 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CBY2 144 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CPB2 144 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ERICH6B 144 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GPALPP1 144 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LRRC63 144 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNASEH2B 144 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC25A30 144 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TPT1 144 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COG3 143 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GTF2F2 143 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCTD4 143 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NUFIP1 143 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZC3H13 143 / 261 cases (55 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAJC15 141 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPSTI1 141 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM124A 141 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | INTS6 141 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERPINE3 141 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLHL1 140 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCDH17 140 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SERP2 140 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMIM2 140 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TSC22D1 140 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WDFY2 140 / 261 cases (54 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AKAP11 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALG11 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | BORA 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC122 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDKN2A 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDKN2B 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CKAP2 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DIS3 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLF5 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LMO7 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MZT1 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | OLFM4 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIBF1 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRR20A 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRR20B 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRR20C 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRR20D 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRR20E 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TBC1D4 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | THSD1 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TNFSF11 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VPS36 139 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATP7B 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COMMD6 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DOCK8 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ENOX1 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM216B 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KLF12 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LACC1 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYH10 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEK3 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NEK5 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCDH9 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UCHL3 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UTP14C 138 / 261 cases (53 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DHRS12 137 / 261 cases (52 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FREM2 137 / 261 cases (52 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HNRNPA1L2 137 / 261 cases (52 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCDH20 137 / 261 cases (52 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PCDH8 137 / 261 cases (52 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | VWA8 137 / 261 cases (52 %) · ssm · TCGA-SARC | — | — | Sarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FOXO3B 68 / 145 cases (47 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TBC1D28 68 / 145 cases (47 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIM16L 68 / 145 cases (47 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDRT4 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EVPLL 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM83G 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FBXW10 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FLII 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GRAP 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LGALS9C 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MIEF2 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PRPSAP2 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SHMT1 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC5A10 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SMCR8 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TOP3A 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TVP23B 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TVP23C 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TVP23C-CDRT4 67 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ADORA2B 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALDH3A1 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALKBH5 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | B9D1 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDRT1 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DRG2 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | EPN2 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GID4 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | GRAPL 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HS3ST3B1 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LGALS9B 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | LLGL1 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAP2K3 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MAPK7 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MFAP4 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTSS1 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYO15A 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NCOR1 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF112 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC47A1 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TATDN1 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TBC1D26 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIM16 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRPV2 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TTC19 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF286A 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZSWIM7 66 / 145 cases (46 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | AKAP10 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ALDH3A2 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATPAF2 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDRT15 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CDRT15L2 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CENPV 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | COX10 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CSMD3 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DNAH9 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DRC3 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FER1L6 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | KCNJ12 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MED9 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MTRNR2L1 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MYC 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NDUFB9 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NT5M 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PIGL 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PLD6 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | PMP22 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | POU5F1B 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RASD1 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | RNF139 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SLC47A2 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SPECC1 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TEKT3 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM65 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRMT12 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | UBB 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ULK2 65 / 145 cases (45 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ASAP1 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATAD2 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CCDC144A 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | CPQ 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DERL1 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | DHRS7B 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FAM91A1 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | FLCN 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | HS3ST3A1 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | MPRIP 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NATD1 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NSMCE2 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | NTAQ1 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | SDC2 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TMEM11 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TOM1L2 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | TRIB1 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | USP22 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | WASHC5 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ZNF572 64 / 145 cases (44 %) · ssm · TARGET-OS | — | — | Osteosarcoma | 1 | Observed | gdc | graph → |
| ← altered in cohorts of | ATRX 25 / 108 cases (23 %) · ssm · usarc_msk_2020 | — | — | Uterine Corpus Sarcoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | CRIPAK 27 / 277 cases (9.7 %) · ssm · lipo_msk_2026 | — | — | Liposarcoma | 1 | Observed | cbioportal | graph → |
| ← altered in cohorts of | ZFHX3 20 / 277 cases (7.2 %) · ssm · lipo_msk_2026 | — | — | Liposarcoma | 1 | Observed | cbioportal | graph → |